3 Stocks Dragging In The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 115 points (0.7%) at 16,388 as of Friday, Feb. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,987 issues advancing vs. 938 declining with 158 unchanged.

The Drugs industry currently sits down 0.5% versus the S&P 500, which is up 0.6%. On the negative front, top decliners within the industry include Questcor Pharmaceuticals ( QCOR), down 7.8%, Isis Pharmaceuticals ( ISIS), down 5.0%, Intercept Pharmaceuticals ( ICPT), down 3.5%, Shire ( SHPG), down 2.5% and Illumina ( ILMN), down 1.6%. Top gainers within the industry include Grifols ( GRFS), up 2.8%, Amgen ( AMGN), up 2.4%, Teva Pharmaceutical Industries ( TEVA), up 1.9%, Sanofi ( SNY), up 0.9% and Novo Nordisk A/S ( NVO), up 0.9%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Drugs industry lower today. As of noon trading, Jazz Pharmaceuticals is down $7.27 (-4.4%) to $159.35 on average volume. Thus far, 726,408 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 985,400 shares. The stock has ranged in price between $159.29-$166.00 after having opened the day at $165.94 as compared to the previous trading day's close of $166.62.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. Jazz Pharmaceuticals has a market cap of $9.4 billion and is part of the health care sector. Shares are up 31.6% year-to-date as of the close of trading on Thursday. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Jazz Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is down $0.92 (-0.6%) to $147.08 on average volume. Thus far, 968,058 shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $146.65-$149.22 after having opened the day at $148.59 as compared to the previous trading day's close of $148.00.

Valeant Pharmaceuticals International, Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics. Valeant Pharmaceuticals International has a market cap of $48.8 billion and is part of the health care sector. Shares are up 26.1% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Valeant Pharmaceuticals International a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and generally higher debt management risk. Get the full Valeant Pharmaceuticals International Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $3.08 (-1.7%) to $180.80 on light volume. Thus far, 385,174 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $180.49-$184.45 after having opened the day at $184.45 as compared to the previous trading day's close of $183.89.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $36.1 billion and is part of the health care sector. Shares are up 37.4% year-to-date as of the close of trading on Thursday. Currently there are 16 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists